{
  "id": 961708,
  "title": "United Therapeutics CEO Martine Rothblatt sells $4.79m in stock",
  "url": "https://urgent.news/2026/08/15/united-therapeutics-ceo-martine-rothblatt-sells-4-79m-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-15T04:46:04.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/united-therapeutics-ceo-martine-rothblatt-sells-479m-in-stock-93CH-4861737"
  },
  "original_language": "en",
  "account": "On August 13, 2026, United Therapeutics CEO Martine Rothblatt sold 9,500 shares of company stock, resulting in a total value of approximately $4.79 million. The shares were sold at prices between $499.46 and $512.64, reflecting a 60% gain over the past year. This sale followed the exercise of stock options, which allowed Rothblatt to acquire an equal number of shares at a price of $135.42 per share, amounting to $1,286,489. Rothblatt's stock sales and option exercises were executed under a pre-arranged 10b5-1 trading plan, which was initiated on November 7, 2025 and will continue until December 31, 2026 or the exercise of 1,734,410 stock options, whichever comes first. As a result of these transactions, Rothblatt now indirectly holds 324,443 shares through a family trust, in addition to her direct and indirect holdings through her spouse and various family trusts. Following her reported transactions, Rothblatt remains the beneficial owner of 324,443 shares of United Therapeutics common stock. United Therapeutics also recently reported its Q2 2026 earnings, with earnings per share of $7.27, surpassing analyst expectations of $7.09. However, the company reported revenue of $783.3 million, falling short of the anticipated $807.05 million, a 2.9% shortfall that has garnered investor attention. In response to the earnings results, BofA Securities reduced its price target for United Therapeutics from $613 to $559, while maintaining a Neutral rating. The mixed sentiment surrounding the company's recent financial performance is influencing investor perceptions and is a crucial factor for those tracking United Therapeutics' progress.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Edgewise Therapeutics CEO Kevin Koch sells $785,042 in stock",
        "url": "https://urgent.news/2026/08/15/edgewise-therapeutics-ceo-kevin-koch-sells-785-042-in-stock",
        "published": "2026-08-15T04:01:04.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}